

EACR-Boehringer Ingelheim Drugging and Regulating the MAP Kinase Pathway Programme

Virtual Event, Worldwide

21 - 22 February 2023



Scientific Programme

Tuesday 21st February 2023

Listed times are in Central European Time (CET)

- 13:00 **WELCOME TO DAY ONE**
Rene Bernards & Marisol Soengas
- SESSION 1: SIGNALLING**
Chairs: Marco Hofmann & Anna Obenauf
- 13:05 **Marco Hofmann**
Boehringer Ingelheim, Austria
"SOS1i combinations enhance the anti-tumor response and overcome resistance"
Q&A 13:25-13:40
- 13:40 **Chiara Ambrogio**
University of Torino, Italy
"Signaling plasticity in pre-clinical models of adaptive and acquired resistance to KRAS-G12C inhibitors"
Q&A 14:00-14:15
- 14:15 **Sara Mainardi**
Netherlands Cancer Institute, Netherlands
Proffered Paper 1: "From bench to bedside and back to bench: identification of potential resistance markers for the SHERPA (SHP2 and ERK inhibition in pancreatic cancer) trial."
Q&A 14:25-14:30
- 14:30 **PROGRAMME BREAK**
- 14:45 **Frank McCormick**
UC San Francisco, USA
"Targeting KRAS and its immediate effectors"
Q&A 15:05-15:20
- 15:20 **Kevan Shokat**
UC San Francisco, USA
"Drugging undruggable targets in cancer"
Q&A 15:40-15:55
- 15:55 **PROGRAMME BREAK**
- SESSION 2: IMMUNE REGULATION**
Chairs: Marisol Soengas & Ralph Neumueller
- 16:10 **Caroline Robert**

Gustave Roussy, France
"Melanoma Persistent cells : Can we track the invisible?"

Q&A 16:30-16:45

16:45 **Roger Lo**
UCLA, USA
'Stabilizing the Genome to Prevent Acquired MAPK Inhibitor Resistance'

Q&A 17:05-17:20

17:20 **POSTER SPOTLIGHTS**
3 top abstracts presented as 3-minute flash talks

17:30 **END OF DAY 1 WEBINAR**
Once the Webinar has ended we will take a 15-minute break before we begin our Virtual Poster Discussion Session 1

17:45 **VIRTUAL POSTER DISCUSSION SESSION 1**
An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

18:45 **END OF DAY ONE**

Wednesday 22nd February 2023

Listed times are in Central European Time (CET)

13:00 **VIRTUAL POSTER DISCUSSION SESSION 2**
An informal and interactive 'virtual' opportunity for participants to browse the posters and make new connections. This 60-minute session will be delivered through the Zoom Meeting platform.

14:00 10-minute transition break (Meeting to Webinar)

14:10 **WELCOME TO DAY TWO**
SESSION 3: RESISTANCE
Chairs: Marco Hofmann & Ralph Neumuller

14:15 **Antreas Hindoyan**
Amgen Inc
"Putative mechanisms of acquired resistance to sotorasib in KRAS p.G12C-mutated NSCLC and CRC: plasma biomarker analysis of CodeBreak 100"

Q&A 14:35-14:50

14:50 **Paolo Armando Gagliardi**
Institute of Cell Biology, Switzerland
Proffered Paper 2: "Targeting apoptosis-induced collective MAPK activity waves to improve breast cancer therapy"

Q&A 15:00-15:05

15:05 **Fernando Calvo Baltanas**
University of Seville, Spain
Proffered Paper 3: "Validation of SOS1/2 RASGEFs as therapeutic targets in KRASG12D-driven lung adenocarcinoma"

Q&A 15:15-15:20

15:20 **PROGRAMME BREAK**

- 15:35 **Anna Obenauf**
Research Institute of Molecular Pathology, Austria
"Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance"
Q&A 15:55-16:10
- 16:10 **Rene Bernards**
The Netherlands Cancer Institute, Netherlands
"Paradoxical activation of oncogenic signaling as a cancer treatment strategy"
Q&A 16:30-16:45
- 16:45 **Julian Downward**
Francis Crick Institute, UK
"KRAS oncogene signalling and the tumour immune microenvironment in lung cancer"
Q&A 17:05-17:20
- 17:20 **SUMMARY AND END OF DAY TWO**
Rene Bernards & Anna Obenauf